At this time, the commercially available Cobas EGFR mutation test is the only technology approved by the United-Stated (US) Food and Drug Administration (FDA) for the molecular analysis of liquid biopsy specimens in NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.